Targeting Homologous Recombination Repair in Cancer - DNA Repair in Cancer Therapy - page 152

210. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal
targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol
Med 2009;1(6-7):315 e 22.
211. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor
suppression. Cell 2008;133(3):403 e 14.
212. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN defi-
ciency in endometrioid endometrial adenocarcinomas predicts
sensitivity to PARP inhibitors. Sci Transl Med 2010;2(53). 53ra75.
213. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear
PTEN in maintaining chromosomal integrity. Cell 2007;128(1):
157 e 70.
214. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K.
Extracellular signal-related kinase positively regulates ataxia
telangiectasia mutated, homologous recombination repair, and
the DNA damage response. Cancer Res 2007;67(3):1046 e 53.
215. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases
synthesis of homologous recombination proteins to offset che-
moresistance and radioresistance. Cancer Res 2008;68(2):605 e 14.
216. Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51
and decreased homologous recombination in hypoxic cancer
cells. Mol Cell Biol 2004;24(19):8504 e 18.
217. Chan N, Pires IM, Bencokova Z, et al. Contextual synthetic
lethality of cancer cell kill based on the tumor microenvironment.
Cancer Res 2010;70(20):8045 e 54.
218. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability e
an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3): 220 e 8.
219. Klein HL. The consequences of Rad51 overexpression for normal
and tumor cells. DNA Repair (Amst) 2008;7(5):686 e 93.
220. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases
induce drug resistance by stimulation of homology-dependent
recombination repair, prolongation of G(2)/M phase, and
protection from apoptosis. Mol Cell Biol 2002;22(12):4189 e 201.
221. Mitra A, Jameson C, Barbachano Y, et al. Overexpression of
RAD51 occurs in aggressive prostatic cancer. Histopathology 2009;
55(6):696 e 704.
222. Maacke H, Opitz S, Jost K, et al. Over-expression of wild-type
Rad51 correlates with histological grading of invasive ductal
breast cancer. Int J Cancer 2000;88(6):907 e 13.
223. Kim PM, Allen C, Wagener BM, Shen Z, Nickoloff JA. Over-
expression of human RAD51 and RAD52 reduces double-strand
break-induced homologous recombination in mammalian cells.
Nucleic Acids Res 2001;29(21):4352 e 60.
224. Flygare J, Falt S, Ottervald J, et al. Effects of HsRad51 over-
expression on cell proliferation, cell cycle progression, and
apoptosis. Exp Cell Res 2001;268(1):61 e 9.
225. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1
deficiency results in early embryonic lethality characterized by
neuroepithelial abnormalities. Nat Genet 1996;12(2):191 e 4.
226. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homol-
ogous recombination, DNA replication fidelity and the cellular
response to ionizing radiation. Oncogene 2003;22(37):5784 e 91.
227. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK.
RAD51 up-regulation bypasses BRCA1 function and is a common
feature of BRCA1-deficient breast tumors. Cancer Res 2007;67(20):
9658 e 65.
228. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS,
Powell SN. Inactivation of p53 results in high rates of homolo-
gous recombination. Oncogene 1997;14(15):1847 e 57.
229. Aky ¨ z N, Boehden GS, S ¨ sse S, et al. DNA substrate dependence
of p53-mediated regulation of double-strand break repair. Mol
Cell Biol 2002;22(17):6306 e 17.
230. Linke SP, Sengupta S, Khabie N, et al. p53 interacts with hRAD51
and hRAD54, and directly modulates homologous recombina-
tion. Cancer Res 2003;63(10):2596 e 605.

231. Saintigny Y, Rouillard D, Chaput B, Soussi T, Lopez BS. Mutant
p53 proteins stimulate spontaneous and radiation-induced
intrachromosomal homologous recombination independently of
the alteration of the transactivation activity and of the G1

checkpoint. Oncogene 1999;18(24):3553 e 63.
232. Willers H, McCarthy EE, Wu B, et al. Dissociation of p53-medi-
ated suppression of homologous recombination from G1/S cell
cycle checkpoint control. Oncogene 2000;19(5):632 e 9.
233. Yun S, Lie ACC, Porter AC. Discriminatory suppression of
homologous recombination by p53. Nucleic Acids Res 2004;32(22):
6479 e 89.
234. Sengupta S, Linke SP, Pedeux R, et al. BLM helicase-dependent
transport of p53 to sites of stalled DNA replication forks modu-
lates homologous recombination. EMBO Journal 2003;22(5):
1210 e 22.
235. Romanova LY, Willers H, Blagosklonny MV, Powell SN. The
interaction of p53 with replication protein A mediates suppres-
sion of homologous recombination. Oncogene 2004;23:9025 e 33.
236. St ¨ rzbecher HW, Donzelmann B, Henning W, Knippschild U,
Buchhop S. p53 is linked directly to homologous recombination
processes via RAD51/RecA protein interaction. EMBO Journal
1996;15(8):1992 e 2002.
237. Gatz SA, Wiesmuller L. p53 in recombination and repair. Cell
Death Differ 2006;13(6):1003 e 16.
238. Rajagopalan S, Andreeva A, Rutherford TJ, Fersht AR. Mapping
the physical and functional interactions between the tumor
suppressors p53 and BRCA2. Proc Natl Acad Sci USA 2010;
107(19):8587 e 92.
239. Arias-Lopez C, Lazaro-Trueba I, Kerr P, et al. p53 modulates
homologous recombination by transcriptional regulation of the
RAD51 gene. EMBO Rep 2006;7(2):219 e 24.
240. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor
gene. Nature 1991;351(6326):453 e 6.
241. Lieberman HB. DNA damage repair and response proteins as
targets for cancer therapy. Curr Med Chem 2008;15(4):360 e 7.
242. Evers B, Helleday T, Jonkers J. Targeting homologous recombi-
nation repair defects in cancer. Trends Pharmacol Sci 2010;31(8):
372 e 80.
243. Legerski RJ. Repair of DNA interstrand cross-links during S
phase of the mammalian cell cycle. Environ Mol Mutagen 2010;
51(6):540 e 51.
244. Bizanek R, McGuinness BF, Nakanishi K, Tomasz M. Isolation
and structure of an intrastrand cross-link adduct of mitomycin C
and DNA. Biochemistry 1992;31(12):3084 e 91.
245. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by
cellular proteins. Mutat Res 2001;478(1-2):1 e 21.
246. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in
interstrand cross-link uncoupling do not account for the extreme
sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res
2002;30(17):3848 e 56.
247. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C,
Perez JM. Biochemical mechanisms of cisplatin cytotoxicity.
Anticancer Agents Med Chem 2007;7(1):3 e 18.
248. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR,
Bishop DK. The breast cancer susceptibility gene BRCA1 is
required for subnuclear assembly of Rad51 and survival
following treatment with the DNA cross-linking agent cisplatin.
J Biol Chem 2000;275(31):23899 e 903.
249. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN,
Helleday T. Spontaneous homologous recombination is induced
by collapsed replication forks that are caused by endogenous
DNA single-strand breaks. Mol Cell Biol 2005;25(16):7158 e 69.
250. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C,
Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to